220 related articles for article (PubMed ID: 7671161)
1. Acute effects of bisphosphonates on new and traditional markers of bone resorption.
Pedrazzoni M; Alfano FS; Gatti C; Fantuzzi M; Girasole G; Campanini C; Basini G; Passeri M
Calcif Tissue Int; 1995 Jul; 57(1):25-9. PubMed ID: 7671161
[TBL] [Abstract][Full Text] [Related]
2. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
3. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
4. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed.
Filipponi P; Pedetti M; Beghe F; Giovagnini B; Miam M; Cristallini S
Bone; 1994; 15(3):261-7. PubMed ID: 8068446
[TBL] [Abstract][Full Text] [Related]
5. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
[TBL] [Abstract][Full Text] [Related]
6. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
Papapoulos SE; Frölich M
J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
[TBL] [Abstract][Full Text] [Related]
8. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease.
Blumsohn A; Naylor KE; Assiri AM; Eastell R
Clin Chem; 1995 Nov; 41(11):1592-8. PubMed ID: 7586548
[TBL] [Abstract][Full Text] [Related]
9. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.
Rosen HN; Dresner-Pollak R; Moses AC; Rosenblatt M; Zeind AJ; Clemens JD; Greenspan SL
Calcif Tissue Int; 1994 Jan; 54(1):26-9. PubMed ID: 8118749
[TBL] [Abstract][Full Text] [Related]
10. Effects of short-term treatment with clodronate on parameters of bone metabolism and their diurnal variation.
Sairanen S; Tähtelä R; Laitinen K; Löyttyniemi E; Välimäki MJ
Calcif Tissue Int; 1997 Feb; 60(2):160-3. PubMed ID: 9056164
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
12. Pamidronate and biochemical markers of bone turnover.
Martínez ME; Del Campo MT; Plaza MA; Torrijos A; Gijón J
Scand J Clin Lab Invest; 1997 Nov; 57(7):581-6. PubMed ID: 9397488
[TBL] [Abstract][Full Text] [Related]
13. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.
Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F
Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463
[TBL] [Abstract][Full Text] [Related]
14. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
[TBL] [Abstract][Full Text] [Related]
15. Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?
Hamdy NA; Papapoulos SE; Colwell A; Eastell R; Russell RG
Bone Miner; 1993 Jul; 22(1):1-8. PubMed ID: 8219934
[TBL] [Abstract][Full Text] [Related]
16. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment.
Gertz BJ; Clemens JD; Holland SD; Yuan W; Greenspan S
Calcif Tissue Int; 1998 Aug; 63(2):102-6. PubMed ID: 9685512
[TBL] [Abstract][Full Text] [Related]
17. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
18. Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared.
Bettica P; Bevilacqua M; Vago T; Masino M; Cucinotta E; Norbiato G
J Clin Endocrinol Metab; 1997 Sep; 82(9):3034-9. PubMed ID: 9284739
[TBL] [Abstract][Full Text] [Related]
19. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
[TBL] [Abstract][Full Text] [Related]
20. Bone resorption in healthy and osteoporotic postmenopausal women: comparison markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links.
Välimäki MJ; Tähtelä R; Jones JD; Peterson JM; Riggs BL
Eur J Endocrinol; 1994 Sep; 131(3):258-62. PubMed ID: 7921210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
